Viewing Study NCT04447027

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 5:11 AM
Ignite Modification Date: 2025-12-26 @ 4:17 AM
Study NCT ID: NCT04447027
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-08-01
First Post: 2020-06-24
Is NOT Gene Therapy: False
Has Adverse Events: True
Brief Title: Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Cutaneous T-Cell Lymphoma View
None Mature T-cell Malignancies View
None Peripheral T-Cell Lymphoma View
None Relapsed/ Refractory T-cell Malignancies View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunomodulatory Drugs (IMiDs) View
None TCM View
None ALCL View
None Histone Deacetylase Inhibitors (HDACi) View